Marc Van den Eynde

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Franck Pagès, Bernhard Mlecnik, Florence Marliot et al. · The Lancet · 2018 · 2K citations

Prognostic Biomarkers, Oncology, International Validation +12

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 543 citations · Full text

Cobimetinib Versus Regorafenib, Oncology, Medicine +10

Evolution of Metastases in Space and Time under Immune Selection

Mihaela Angelova, Bernhard Mlecnik, Angela Vasaturo et al. · Cell · 2018 · 452 citations · Full text

Systems Biology, Immune Selection, Immunology +9

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients

Marc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea et al. · Cancer Cell · 2018 · 278 citations · Full text

Immune Evasion, Cancer Immunosurveillance, Medicine +8

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6